Fig. 6
From: SP1 promotes triple-negative breast cancer progression by targeting USP5
Periplocin acts as a USP5 inhibitor and inhibits TNBC progression. (A) The mode of periplocin binding with USP5 was generated using Molecular Operating Environment (MOE) software. (B) Structural formula of periplocin. (C) Representative immunoblots from a cellular thermal shift (CETSA) assay showing the stabilization of USP5 by periplocin. (D) USP5-mediated UB-AMC hydrolysis treatment with vehicle or periplocin (100nM). (E-I) shCtrl/231 and shUSP5/231 cells proliferation following 100nM periplocin treatment was evaluated using CCK8 assay (E), clonogenic assay (F, G), and EDU incorporation assay (H, I). ***P < 0.001, **P < 0.01, *P < 0.05. (J) Images of nude mice with xenograft tumors in each group. (K) Tumor growth curve of nude mice in each group. ***P < 0.001, *P < 0.05. (L) Tumor weight of nude mice in each group. ***P < 0.001, *P < 0.05. (M) Schematic diagram of periplocin inhibits triple-negative breast cancer progression by targeting SP1-USP5 axis (drawn using ChemDraw software)